Disease-modifying agents for multiple sclerosis: recent advances and future prospects. - Wikidata - wikimedia - TriplyDB

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

http://www.wikidata.org/entity/Q37328280

about

Adverse effects of biologics: a network meta-analysis and Cochrane overview Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury.Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Inhibitory role for GABA in autoimmune inflammation.Cladribine tablets: in relapsing-remitting multiple sclerosis.Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial Magnetic resonance imaging reveals slow-down of global cerebral oxygen metabolism in multiple sclerosis Longitudinal Evaluation of Visual Function in Multiple Sclerosis.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.Treatment options for multiple sclerosis: current and emerging therapies.Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.Novel treatment for immune neuropathies on the horizon.Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.B cell-targeted therapies in autoimmunity: rationale and progress.United Europeans for development of pharmacogenomics in multiple sclerosis network.Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis.Targeting calpain-mediated proteolysis and peptide signaling as a strategy to reduce injury in multiple sclerosis.A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis Fluorescence Correlation Spectroscopy Reveals Efficient Cytosolic Delivery of Protein Cargo by Cell-Permeant Miniature Proteins

P2860

Q24234197-61AEFC06-3A29-49A5-A32F-8553E0BF1350 Q30432124-B2BCE945-B5C2-4EBB-8CEC-A1B7CDC43CA8 Q30659100-B60EFD80-2077-44C0-BE1F-8E33016AA49E Q30699740-14A8AED7-8947-4074-AEEC-E545F0AC4145 Q33664659-B280172C-C07E-48C3-8099-3652077F7A47 Q33821160-F686FEFC-A2E2-42B3-AA3B-AD4A20793F5C Q33832088-D118E2E1-9DB8-4711-AC36-394C7511AB5C Q34028864-700D66CD-26A3-4022-907D-7B566F8005EB Q34040939-51FE57BE-2BFD-4ED5-B959-16B534CEA396 Q34267149-59212984-BF59-4521-B588-D85BE5D357C2 Q34409297-279EE59E-977A-491F-96D6-6265BBE0A175 Q34465400-B5FDA62D-D246-48B2-90AD-FD88D889E374 Q35016997-742851E8-1768-4D84-AFA2-B1938F0AA256 Q35544804-4B56DF42-F01E-4F64-83C8-4694EC830C5B Q35800543-B3F96A0C-77A7-4C61-B996-5A5C43FBF9A7 Q36090219-194B6DE7-A311-454E-87B6-609BB1F7AC2C Q36223650-0939AE50-D5F3-451B-95B7-26F624487628 Q36373827-11D629D7-EAD0-4C86-B4FD-A89289607AA3 Q37523986-C4C30598-D7E5-42A3-BC72-581573AA81E9 Q37783296-7F2778C4-4139-474C-85A1-600ADDCF32B1 Q37800214-2FEF732B-33DF-40AF-93FF-58505F192FD0 Q37814815-CBC3826A-74BE-4A13-BD29-F74E9AEE7CCD Q37892641-7CA0FC04-7AC6-4C47-9397-6E1480BDBF88 Q37905767-19DD6EE0-067B-4953-92C4-B2EC3733BD21 Q38152977-05AA618C-5A19-4C8C-9203-50883C3B5A6C Q38195521-8D5ED7E5-6143-4C2B-97E9-DE9789A9F5C9 Q41903365-A77B0EE4-0C0E-4E98-9A33-453C03FAC26F Q43838731-7D1BF5F9-7946-4C62-8231-152022DE54C6 Q48586779-62FCDB36-E7D5-4BAB-AB94-948EC75615B6 Q51733897-5F229997-9183-4532-A09F-809D1759A7CE Q57430578-EBB61F33-382A-4E87-A362-F6FB8AD38AF3 Q58564633-47CDB113-61AE-4A28-8A02-47DB7507EC1F

P2860

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

http://www.wikidata.org/entity/Q37328280

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

@en

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

@nl

type

label

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

@en

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

@nl

prefLabel

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

@en

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

@nl

P1433

Q37328280-0978AC4E-305A-4BDD-8BA9-4BB0E3AE0B0A

P1476

Q37328280-0F027266-3BF2-4A62-8EBA-41C6F53BEAD6

P2093

Q37328280-06166622-4644-4926-81D8-4B1EFDAA868A

Q37328280-0DC9E5FC-6E10-4D24-88BA-BBA7CB3F29AD

Q37328280-1D2B3BED-FFA7-4BF6-A85E-5AA3D6C4909B

Q37328280-8206F962-843D-47ED-9988-E7C1D06A5640

Q37328280-853941EE-1FAE-4003-B4FD-23CD21D15974

Q37328280-8A54450A-E1C5-492A-9370-FB877EBF89D4

Q37328280-A3695C42-515B-42EA-9C8E-17A8234BB8A2

Q37328280-C5B47663-D04E-4389-BDB8-0385F36A17A4

P2860

Q37328280-031B6435-B85C-431B-B8A5-A51472997CC5

Q37328280-11A671E1-7A02-4F58-AE90-9B4C94CB3E5D

Q37328280-12C89942-E9F2-47D2-80D5-3BE30A4A8CE7

Q37328280-23370EF7-04D4-4344-8CAC-C3C8BC244B88

Q37328280-39513901-1CB5-4702-A546-7DC560FD7272

Q37328280-444BDC84-01B2-45A9-AC88-D1F60706C94A

Q37328280-44D667CD-CC51-4E70-B98A-6024A31025D0

Q37328280-58DC9E1D-B730-429C-98DD-FF33075EAA1E

Q37328280-60004196-2247-4569-AB57-5AD4973EF5BE

Q37328280-A23A9342-0947-4262-88F9-E8283CC74B68

P2888

Q37328280-12D82647-53B0-4081-B9E6-3CBABE362236

P304

Q37328280-E0950504-CAAA-4F1D-92C7-54F0D68215EC

P31

Q37328280-EFB3B883-3DBC-44AB-A629-603C7966831F

P356

Q37328280-133382E2-6283-4571-9FFF-66F7CF032482

P433

Q37328280-157F6503-6EBD-418B-A35D-BBFED619AE95

P478

Q37328280-6D0596A6-3B26-4391-90B0-1FF697941745

P50

Q37328280-3BD360C9-F713-496C-9373-BC028E3E62EF

Q37328280-57D05593-C5A5-4996-803A-B26021C34B3D

Q37328280-5C36D671-5593-4E2A-A0DB-3B8567DBAC8D

P577

Q37328280-F209B72B-3FB9-4D75-AE0F-629FFC70876C

P6179

Q37328280-AEF7A2DC-A471-4A36-B013-8DE8EA8B57E9

P698

Q37328280-2B95B375-CC5F-4D86-9DFA-EF264CCEC727

P921

Q37328280-44BAA034-CED6-43A4-B35D-0004770B6A45

P356

0003495-200868170-00004

P1433

P1476

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

@en

P2093

Aaron Boster

http://www.w3.org/2001/XMLSchema#string

Bernhard Hemmer

http://www.w3.org/2001/XMLSchema#string

Clemens Warnke

http://www.w3.org/2001/XMLSchema#string

Hans-Christian von Büdingen

http://www.w3.org/2001/XMLSchema#string

Martin S Weber

http://www.w3.org/2001/XMLSchema#string

Omar Khan

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

Til Menge

http://www.w3.org/2001/XMLSchema#string

P2860

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.

An open trial of OKT3 in patients with multiple sclerosis.

Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients.

P2888

0003495-200868170-00004

P304

2445-2468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/0003495-200868170-00004

http://www.w3.org/2001/XMLSchema#string

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Hartung

Bernd C Kieseier

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1040444661

http://www.w3.org/2001/XMLSchema#string

P698

19016573

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis